Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMDA Stock Price Chart Interactive Chart >
GMDA Price/Volume Stats
| Current price | $1.59 | 52-week high | $4.72 |
| Prev. close | $1.69 | 52-week low | $1.10 |
| Day low | $1.58 | Volume | 480,345 |
| Day high | $1.70 | Avg. volume | 457,659 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 117.89M |
Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Latest GMDA News From Around the Web
Below are the latest news stories about GAMIDA CELL LTD that investors may wish to consider to help them evaluate GMDA as an investment opportunity.
Gamida Cell Announces Closing of $25 Million Financing With HighbridgeBOSTON, December 12, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, "Highbridge"). Pursuant to the loan agreement, Gamida Cell’s wholly-owned subsidiary, as borrower, will draw down $25 million from the fac |
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor ConferencesBOSTON, November 23, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: |
JMP Securities Remains a Buy on Gamida Cell (GMDA)JMP Securities analyst Jason Butler reiterated a Buy rating on Gamida Cell (GMDA - Research Report) today and set a price target of $15.00. The company's shares opened today at $1.40.According to TipRanks, Butler is an analyst with an average return of -9.8% and a 39.54% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cytokinetics, Aquestive Therapeutics, and Prothena.Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $12.40, a 785.71% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $8.00 price target. |
Needham Sticks to Their Buy Rating for Gamida Cell (GMDA)Needham analyst Gil Blum reiterated a Buy rating on Gamida Cell (GMDA - Research Report) today and set a price target of $8.00. The company's shares opened today at $1.40.Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Gamida Cell. According to TipRanks, Blum has an average return of -23.9% and a 27.92% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $12.40 average price target, representing a 785.71% upside. |
GMDA Down After FDA Extends Review For Lead CandidateShares of Gamida Cell (NASDAQ: GMDA) plunged in morning trading on Tuesday after the company developing NAM-enabled cell therapies for cancer patients gave a regulatory update. The company stated that the U.S. FDA extended the review period for its application for its advanced cell therapy candidate, lead candidate omidubicel. GMDA stated that as a part of the review of its Biologics License Application (BLA) for omidubicel, the U.S. FDA had extended the Prescription Drug User Fee Act (PDUFA) date from January 30 next year to May 1, 2023. The company added that the FDA had "also rescheduled Gamida Cell’s late-cycle meeting to the first quarter of 2023. |
GMDA Price Returns
| 1-mo | 12.77% |
| 3-mo | -14.52% |
| 6-mo | -47.18% |
| 1-year | -48.54% |
| 3-year | -65.73% |
| 5-year | N/A |
| YTD | 23.26% |
| 2022 | -49.21% |
| 2021 | -69.73% |
| 2020 | 95.12% |
| 2019 | -56.74% |
| 2018 | N/A |
Loading social stream, please wait...